ArticleEuropean journal of hospital pharmacy : science and practice2022

Cost-effectiveness analysis of pembrolizumab plus standard chemotherapy versus chemotherapy alone for first-line treatment of metastatic non-squamous non-small-cell lung cancer in China.

Yuan Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.